Furthermore, MS in AML was enriched with mutations of the RTK-RAS pathway genes (KRAS, NRAS, BRAF, PTPN11, and CBL) (15), while KRAS and NRAS mutations occupy 70% (16). The gene discussed is KRAS; the disease is acute myeloid leukemia.